ANDREW BAKER - Partner
GBS Venture Partners
Dr Andrew Baker joined GBS in 2002 with over 18 years experience in the pharmaceutical and biotechnology industries, including 14 years working with industry leaders Genentech, Bayer and Johnson & Johnson. At GBS, he has been focused on investing in early stage, life science opportunities and is on the board of Cryptopharma, Spinifex, Verva, Hatchtech and Xenome.
Andrew has an honours in science from the University of Sydney and a PhD from the Australian National University in Canberra.
